While well-established in the younger patient population, the prognostic significance of NPM1 and FLT3-ITD within geriatric patients is less clear, although recent studies have examined this within various AML study groups and registries.32,33 This current study uses a large real-world cohort of adult patients with AML treated at either Veterans Health Administration or an academic institution to investigate the prognostic implications of NPM1 and FLT3-ITD mutations in those over 65 years old compared to patients under 65 years old. This evidence concerns the gene NPM1 and acute myeloid leukemia.